A new anabolic compound, LLP2A-Ale, reserves periodontal bone loss in mice through augmentation of bone formation.
Min JiangLixian LiuRuiwu LiuKit S LamNancy E LaneWei YaoPublished in: BMC pharmacology & toxicology (2020)
Our findings indicated that LLP2A-Ale treatment rescued alveolar bone loss caused by PD, primarily by increasing bone formation. LLP2A-Ale also attenuated the circulating levels of a series of inflammatory cytokines and reversed the PD-induced suppression of systemic bone formation.